NCT06853951 Cardioprotection on Chemotherapy-Induced Cardiotoxicity
| NCT ID | NCT06853951 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Ain Shams University |
| Condition | Cardiotoxicity |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-07-18 |
| Primary Completion | 2025-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 30 participants in total. It began in 2023-07-18 with a primary completion date of 2025-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the present study is to evaluate the protective impact of cardioprotective medications on the chemotherapy- induced cardiotoxicity.
Eligibility Criteria
Inclusion Criteria: * Willingness of the legal representative of research participant to participate in the study by giving "informed consent." * Ability to take oral medication. * Age 2-18 years at the time of diagnosis. Exclusion Criteria: * Documented allergy to cardioprotective medications
Contact & Investigator
Manal Hamed El-Hamamsy, Prof
PRINCIPAL INVESTIGATOR
Ain Shams University
Frequently Asked Questions
Who can join the NCT06853951 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 18 Years, studying Cardiotoxicity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06853951 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 30 participants.
Is NCT06853951 currently recruiting?
Yes, NCT06853951 is actively recruiting participants. Contact the research team at keristin.nazir21@pharma.asu.edu.eg for enrollment information.
Where is the NCT06853951 trial being conducted?
This trial is being conducted at Cairo, Egypt, Cairo, Egypt.
Who is sponsoring the NCT06853951 clinical trial?
NCT06853951 is sponsored by Ain Shams University. The principal investigator is Manal Hamed El-Hamamsy, Prof at Ain Shams University. The trial plans to enroll 30 participants.